OXFORD, England--(BUSINESS WIRE)--PharmaVentures is pleased to announce that it has acted as advisor to MedGenesis Therapeutix, Inc. (MedGenesis) in their recently announced agreement with Pfizer. MedGenesis’ unique therapeutic approach, which will be used in the clinical development of potential treatments for Parkinson’s disease, delivers GDNF (glial cell-derived neurotrophic factor) precisely to the regions of the brain where it is required via its convection enhanced delivery (CED) technology.
Help employers find you! Check out all the jobs and post your resume.
